Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.6.2445

RNA Interference as a Plausible Anticancer Therapeutic Tool  

Ramachandran, Puthucode Venkatakrishnan (Entomology Research Institute, Loyola College)
Ignacimuthu, Savarimuthu (Entomology Research Institute, Loyola College)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.6, 2012 , pp. 2445-2452 More about this Journal
Abstract
RNA interference has created a breakthrough in gene silencing technology and there is now much debate on the successful usage of RNAi based methods in treating a number of debilitating diseases. Cancer is often regarded as a result of mutations in genomic DNA resulting in faulty gene expression. The occurrence of cancer can also be influenced by epigenetic irregularities in the chromatin structure which leads to alterations and mutations in DNA resulting in cancer cell formation. A number of therapeutic approaches have been put forth to treat cancer. Anti cancer therapy often involves chemotherapy targeting all the cells in common, whereby both cancer cells as well as normal cells get affected. Hence RNAi technology has potential to be a better therapeutic agent as it is possible to deactivate molecular targets like specific mutant genes. This review highlights the successful use of RNAi inducers against different types of cancer, thereby paving the way for specific therapeutic medicines.
Keywords
siRNA treatment; miRNA; lung cancer; liver cancer; gynecologic cancers; urologic cancers;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sioud M, Sorensen DR (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun, 312, 1220-5.   DOI
2 Song E, Zhu P, Lee SK, et al (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol, 23,709-17.   DOI
3 Sorensen DR, Leirdal M, Sioud M (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol, 327, 761-6.   DOI   ScienceOn
4 Soutschek J, Akinc A, Bramlage B, et al (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-8.   DOI   ScienceOn
5 Sui G, Soohoo C, Affarel B, et al (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA, 99, 5515-20.   DOI   ScienceOn
6 Sutton D, Kim S, Shuai X, et al (2006). Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine, 1, 155-62.   DOI
7 Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T (2004). A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res, 64, 3365-70.   DOI   ScienceOn
8 Tan WB, Jiang SY, Zhang Y (2007). Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials, 28, 1565-71.   DOI
9 Valdehita A, Carmena MJ, Bajo AM, Prieto JC (2012). RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol, 348, 241-6.   DOI
10 Wang Y, Gao S, Ye WH, Yoon HS, Yang YY (2006). Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer, Nat Mater, 5, 791-6.   DOI
11 Wang Y, Zhu H, Quan L (2005). Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther, 4, 974-8.   DOI
12 Wang ZX, Dong X, Liu ZL, et al (2012). Overexpression of polo-like kinase 1 and its clinical significance in human nonsmall cell lung cancer. Int J Biochem Cell Biol, 44, 200-10.   DOI
13 Wilda M, Fuchs U, Wossmann W, Borkhardt A (2002). Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene, 21, 5716-24.   DOI
14 Withey JM, Marley SB, Kaeda J (2005). Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol, 129, 377-80.   DOI
15 Wohlbold L, Van der Kuip H, Miething C, et al (2003). Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood, 102, 2236-9.   DOI
16 Xu CX, Jere D, Jin H, et al (2008). Poly (ester amine)-mediated, aerosol delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med, 178, 60-73.   DOI
17 Yang G, Cai KQ, Thompson-Lanza JA, Bast Jr RC, Liu J (2004). Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem, 279, 4339-45.
18 Yano J, Hirabayashi K, Nakagawa S, et al (2004). Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res, 10, 7721-6.   DOI
19 Zamore PD, Tuschl T, Sharp PA, Bartel DP (2000). RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101, 25-33.   DOI   ScienceOn
20 Yoshinouchi M, Yamada T, Kizaki M, et al (2003). In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther, 8, 762- 8.   DOI   ScienceOn
21 Zeng Y, Yi R, Cullen B (2005). Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J, 24, 138-48.   DOI
22 Zhang A, Liu Y, Shen Y, et al (2010). Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells. Med Oncol, 27, 1179-84.   DOI
23 Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W (2004). Single processing center models for human Dicer and bacterial RNase III. Cell, 118, 57-68.   DOI   ScienceOn
24 Zhang T, Guan M, Jin H, Lu Y (2005). Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol Oncol, 97, 501- 7.   DOI
25 Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001). Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409, 363-6.   DOI   ScienceOn
26 Ahlquist P (2002). RNA-dependent RNA polymerases, viruses and RNA silencing. Science, 296, 1270-3.   DOI
27 Arbuthnot P, Longshaw V, Naidoo T, Weinberg MS (2007). Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat, 14, 447-59.   DOI
28 Bahi A, Boyer F, Kolira M, Dreyer JL (2005). In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J Neurochem, 92, 1243-55.   DOI
29 Bisanz K, Yu J, Edlund M, et al (2005). Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther, 12, 634-43.   DOI
30 Brummelkamp TR, Bernards R, Agami R (2002a). A system for stable expression of short interfering RNAs in mammalian cells. Science, 296, 550-3.   DOI
31 Brummelkamp TR, Bernards R, Agami R (2002b). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2, 243-7.   DOI   ScienceOn
32 Caldas H, Holloway MP, Hall BM, Qualman SJ, Altura RA (2006). Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet, 43, 119-28.
33 Cheng AM, Byrom MW, Shelton J, Ford LP (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res, 33, 1290-7.   DOI   ScienceOn
34 Calin GA, Dumitru CD, Shimizu M, et al (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukaemia. Proc Natl Acad Sci USA, 99, 15524-29.   DOI   ScienceOn
35 Calin GA, Sevignani C, Dumitru, CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 101, 2999-3004.   DOI   ScienceOn
36 Chan JA, Krichevsky AM, Kosik KS (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res, 65, 6029-33.   DOI
37 Chien PY, Wang J, Carbonaro D, et al (2005). Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther, 12, 321-8.   DOI
38 Cory S, Adams JM (2005). Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell, 8, 5-6.   DOI
39 Danilin S, Sourbier C, Thomas L, et al (2010). Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis, 31, 1018-26.   DOI
40 Dittgen T, Nimmerjahn A, Komai S, et al (2004). Lentivirusbased genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proc Natl Acad Sci USA, 101, 18206-11.   DOI
41 Eckerdt F, Yuan J, Strebhardt K (2005). Polo-like kinases and oncogenesis. Oncogene, 24, 267-76.   DOI
42 Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E (2004). AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol, 94, 785-95.   DOI
43 Eis PS, Tam W, Sun L, et al (2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA, 102, 3627-32.   DOI
44 Fu GF, Lin XH, Han QW (2005). RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo. Cancer Biol Ther, 4, 822-9.   DOI
45 Fujii T, Saito M, Iwasaki E, et al (2006). Intratumor injection of small interfering RNA- targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncol, 29, 541-8.
46 Gao LF, Xu DQ, Wen LJ, et al (2005). Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol. Sin, 26, 377-83.   DOI
47 Green VA, Weinberg MS (2011). Small RNA-induced transcriptional gene regulation in mammals: mechanisms, therapeutic applications, and scope within the genome. Prog Mol Biol Transl Sci, 102, 11-46.   DOI
48 Hamilton AJ, Baulcombe DC (1999). A species of small antisense RNA in post transcriptional gene silencing in plants. Science, 286, 950-2.   DOI   ScienceOn
49 Hemann MT, Fridman JS, Zilfou JT, et al (2003). An Epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet, 33, 396-400.   DOI
50 Hosono T, Mizuguchi H, Katayama K, et al (2005). RNA interference of PPARgamma using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells. Gene, 348, 157-65.   DOI
51 Hutvagner G ( 2005). Small RNA asymmetry in RNAi: Function in RISC assembly and gene regulation. FEBS Lett, 579, 5850-7.   DOI
52 Howard BA, Furumai R, Campa MJ, et al (2005). Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res, 65, 8853-60.   DOI
53 Hua J, Mutch DG, Herzog TJ (2005). Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol Oncol, 98, 31-8.   DOI   ScienceOn
54 Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res, 65, 8984-92.   DOI
55 Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.   DOI   ScienceOn
56 Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. Cancer J Clin, 60, 277-300.   DOI
57 Jiang M, Milner J (2005). Selective silencing of viral gene E6 and E7 expression in HPV-positive human cervical carcinoma cells using small interfering RNAs. Methods Mol Biol, 292, 401-20.
58 July LV, Beraldi E, So A, et al (2004). Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther, 3, 223-32.   DOI
59 Karasarides M, Chiloeches A, Hayward R, et al (2004). B-RAF is a therapeutic target in melanoma. Oncogene, 23, 6292-8.   DOI   ScienceOn
60 Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC (2003). Survivin and molecular pathogenesis of colorectal cancer. Lancet, 362, 205-9.   DOI
61 Kim VN (2005). MicroRNA biogenesis: coordinated cropping and dicing. Nature Rev Mol Cell Biol, 6, 376-85.   DOI
62 Kluiver J, Poppema S, De Jong D, et al (2005). BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol, 207, 243-9.   DOI
63 Ku JH, Seo SY, Kwak C, et al (2010). Cytotoxicity and apoptosis by survivin small interfering RNA in bladder cancer cells. BJU Int, 106, 1812-6.   DOI
64 Kunze D, Wuttig D, Fuessel S, et al (2008). Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res, 28, 2259-63.
65 Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY (2004). CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther, 12, 84-9.
66 Lee NS, Dohjima T, Bauer G, et al (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol, 20, 500-5.
67 Lee SO, Lou W, Qureshi KM, et al (2004). RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate, 60, 303-9.   DOI
68 Li H, Fu X, Chen Y, et al (2005a). Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology, 128, 2029-41.   DOI
69 Li S, Crothers J, Haqq CM, Blackburn EH (2005b). Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interferencemediated depletion of telomerase RNA. J Biol Chem, 280, 23709-17.   DOI
70 Li SD, Chen YC, Hackett MJ, Huang L (2008). Tumor-targeted delivery of siRNA by self assembled nanoparticles, Mol Ther, 16, 163-69.   DOI
71 Li SD, Huang L (2006). Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm, 3, 579-88.   DOI
72 Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH (2004). Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther, 11, 309-16.   DOI
73 Ling X, Li F (2004). Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques, 36, 450-60.
74 McNamara II JO, Andrechek ER, Wang Y, et al (2006). Cell typespecific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 24, 1005-15.   DOI
75 Meryet-Figuières M, Resina S, Lavigne C, et al (2007). Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range. Biochimie, 89, 1228-33.   DOI   ScienceOn
76 Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A (2004). High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer, 39, 167-9.   DOI
77 Miyamoto S, Hirata M, Yamazaki A, et al (2004). Heparinbinding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res, 64, 5720-7.   DOI
78 Morrissey DV, Blanchard K, Shaw L, et al (2005). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology, 41, 1349-56.   DOI   ScienceOn
79 Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS (2002). Short hairpin RNAs (shRNAs) induce sequencespecific silencing in mammalian cells. Genes Dev, 16, 948-58.   DOI   ScienceOn
80 Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T (2005). ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res, 65, 10680-85.   DOI
81 Pal A, Ahmad A, Khan S, et al (2005). Systemic delivery of Raf siRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol, 26, 1087-91.
82 Paul CP, Good PD, Winer I, Engelke DR (2002). Effective expression of small interfering RNA in human cells. Nat Biotechnol, 20, 505-8.   DOI   ScienceOn
83 Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D (2005). In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res, 11, 4487-94.   DOI   ScienceOn
84 Ragozin S, Niemeier A, Laatsch A, et al (2005). Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol, 25, 1433-8.   DOI
85 Rochester MA, Riedemann J, Hellawell GO, et al (2005). Silencing of the IGF1R gene enhances sensitivity to DNAdamaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther, 12, 90-100.   DOI
86 Ronkainen H, Vaarala MH, Hirvikoski P, Ristimaki A (2011). HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol, 32, 481-7.   DOI
87 Scherr M, Battmer K, Schultheis B, Ganser A, Eder M (2005). Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Ther, 12, 12-21.   DOI